Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Glycomimetics Inc (NQ: GLYC )

1.850 +0.050 (+2.78%)
Streaming Delayed Price Updated: 10:05 AM EDT, May 1, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Glycomimetics Inc

< Previous 1 2 3 Next >
GlycoMimetics Announces New Uproleselan Clinical Data in Both Frontline Unfit and Treated Secondary Acute Myeloid Leukemia Will Be Presented at ASH Annual Meeting
From GlycoMimetics, Inc.
Via Business Wire
GlycoMimetics to Report Third Quarter Financial Results on November 9, 2022
From GlycoMimetics, Inc.
Via Business Wire
GlycoMimetics Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
From GlycoMimetics, Inc.
Via Business Wire
GlycoMimetics to Participate in Upcoming H.C. Wainwright 24th Annual Global Investment Conference
From GlycoMimetics, Inc.
Via Business Wire
GlycoMimetics Appoints Edwin Rock, M.D., Ph.D. as Chief Medical Officer
From GlycoMimetics, Inc.
Via Business Wire
GlycoMimetics Reports Highlights and Financial Results for Second Quarter 2022
From GlycoMimetics, Inc.
Via Business Wire
GlycoMimetics to Report Second Quarter Financial Results on August 3, 2022
From GlycoMimetics, Inc.
Via Business Wire
GlycoMimetics to Participate at Upcoming Jefferies 2022 Healthcare Conference
From GlycoMimetics, Inc.
Via Business Wire
GlycoMimetics Reports Highlights and Financial Results for First Quarter 2022
From GlycoMimetics, Inc.
Via Business Wire
GlycoMimetics to Report First Quarter Financial Results on April 28, 2022
From GlycoMimetics, Inc.
Via Business Wire
GlycoMimetics to Report Fourth Quarter and 2021 Year-End Financial Results on March 3, 2022
From GlycoMimetics, Inc.
Via Business Wire
GlycoMimetics Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
From GlycoMimetics, Inc.
Via Business Wire
GlycoMimetics Appoints Bruce Johnson Senior Vice President and Chief Commercial Officer
From GlycoMimetics, Inc.
Via Business Wire
Two GlycoMimetics Posters at 63rd ASH Annual Meeting Highlight Potential of GMI-1359, a Dual Antagonist of CXCR4 and E-selectin
From GlycoMimetics, Inc.
Via Business Wire
NCI-Sponsored Trial of Uproleselan in Older, Newly Diagnosed AML Patients Fit for Intensive Chemotherapy Completes Enrollment of Phase 2 Portion Ahead of Schedule
From GlycoMimetics, Inc.
Via Business Wire
Apollomics Inc. Doses First Patient in Phase 3 Clinical Trial in China of GlycoMimetics’ Uproleselan for the Treatment of AML
From GlycoMimetics, Inc.
Via Business Wire
GlycoMimetics Appoints Regulatory Veteran Lisa DeLuca as Vice President, Regulatory Affairs
From GlycoMimetics, Inc.
Via Business Wire
GlycoMimetics Completes Enrollment of Phase 3 Registration Trial Evaluating Lead Candidate Uproleselan in Patients with Relapsed /Refractory Acute Myeloid Leukemia (AML)
From GlycoMimetics, Inc.
Via Business Wire
GlycoMimetics GMI-1359 Data Selected for Presentation at 63rd American Society of Hematology (ASH) Annual Meeting and Exposition
From GlycoMimetics, Inc.
Via Business Wire
GlycoMimetics to Present at Two Upcoming Healthcare Investor Conferences
From GlycoMimetics, Inc.
Via Business Wire
GlycoMimetics Reports Highlights and Financial Results for Third Quarter 2021
From GlycoMimetics, Inc.
Via Business Wire
GlycoMimetics to Report Third Quarter Financial Results on November 2, 2021
From GlycoMimetics, Inc.
Via Business Wire
Efficacy and Safety Data for GlycoMimetics’ Lead Investigational Drug Uproleselan Published in BLOOD
From GlycoMimetics, Inc.
Via Business Wire
GlycoMimetics to Present at Upcoming H.C. Wainwright & Co Annual Global Investment Virtual Conference
From GlycoMimetics, Inc.
Via Business Wire
GlycoMimetics Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
From GlycoMimetics, Inc.
Via Business Wire
GlycoMimetics Reports Highlights and Financial Results for Second Quarter 2021
From GlycoMimetics, Inc.
Via Business Wire
GlycoMimetics Names Harout Semerjian as New Chief Executive Officer to Succeed Retiring CEO Rachel King
From GlycoMimetics, Inc.
Via Business Wire
GlycoMimetics to Report Second Quarter Financial Results on August 5, 2021
From GlycoMimetics, Inc.
Via Business Wire
Trial Launches to Evaluate GlycoMimetics’ Uproleselan Added to Cladribine Plus Low-Dose Cytarabine in AML Patients
From GlycoMimetics, Inc.
Via Business Wire
GlycoMimetics Announces Initiation of Clinical Trial Evaluating Uproleselan in Combination With Venetoclax and Azacitidine
From GlycoMimetics, Inc.
Via Business Wire
< Previous 1 2 3 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.